Clinical Trial Update: Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update assessing exenatide's effects on glycemic control and weight in people with Type 2 diabetes treated with continuous subcutaneous insulin i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: University Hospital, Caen | Conditions: Type 2 Diabetes | Phase 2, Phase 3 | Status: UNKNOWN